Eli Lilly (LLY) Stock: Why This $2.4 Billion Deal Could Reshape Cell Therapy

TLDR Eli Lilly (LLY) will acquire Orna Therapeutics for up to $2.4 billion in cash to advance cell therapy treatments for autoimmune diseases. Orna is developing ORN-252, a clinical trial-ready in vivo CAR-T therapy that uses circular RNA technology to treat B cell-driven autoimmune diseases. The acquisition gives Lilly access to Orna’s platform that allows [...]

The post Eli Lilly (LLY) Stock: Why This $2.4 Billion Deal Could Reshape Cell Therapy appeared first on Blockonomi.